| Phase I Study of Immune Ablation and CD34+ Peripheral Blood Stem Cell Support in Patients With Systemic Lupus Erythematosus (NCT00017641) | Northwestern Memorial Hospital | 2001-04-01 |
| Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders (NCT00010335) | Fred Hutchinson Cancer Center | 2000-11-01 |
| Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus (NCT00006133) | National Center for Research Resources (NCRR) | 2000-06-01 |
| Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases (NCT00006055) | Fairview University Medical Center | 2000-03-01 |
| Study of GL701 in Men With Systemic Lupus Erythematosus (NCT00037128) | Genelabs Technologies | 1998-03-01 |
| Cyclophosphamide and Fludarabine to Treat Lupus Nephritis (NCT00001676) | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 1998-01-01 |
| Effect of Hormone Replacement Therapy on Lupus Activity (NCT00392093) | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 1997-11-01 |
| Prevention of Arthritis-Related Work Disability (NCT00000416) | Boston University Charles River Campus | 1997-09-01 |
| Safety of Estrogens in Lupus: Birth Control Pills (NCT00000420) | NYU Langone Health | 1997-06-01 |
| Psychoeducational Approach to Improve Health in Lupus (NCT00000417) | Brigham and Women's Hospital | 1997-04-01 |
| Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome (NCT00010400) | Johns Hopkins University | 1997-04-01 |
| Hormonal and Environmental Risk Factors for Developing Systemic Lupus Erythematosus: The Carolina Lupus (CLU) Study (NCT00342095) | National Institute of Environmental Health Sciences (NIEHS) | 1996-12-17 |
| Genetic Study of Lupus Patients and Their Families (NCT00235378) | Oklahoma Medical Research Foundation | 1996-07-01 |
| Safety of Estrogens in Lupus: Hormone Replacement Therapy (NCT00000419) | NYU Langone Health | 1996-04-01 |
| Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Active Systemic Lupus Erythematosus (NCT00004662) | National Center for Research Resources (NCRR) | 1996-03-01 |
| Lupus Genetics Studies (NCT00071175) | Oklahoma Medical Research Foundation | 1995-10-01 |
| Phase II Study of Long-Term Dehydroepiandrosterone for Systemic Lupus Erythematosus (NCT00004665) | National Center for Research Resources (NCRR) | 1995-06-01 |
| Study of Methotrexate in Lupus Erythematosus (NCT00470522) | University Health Network, Toronto | 1995-06-01 |
| Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity (NCT03941184) | Mayo Clinic | 1995-01-01 |
| Study of Individualized Instruction Versus Pamphlet in Systemic Lupus Erythematosus (NCT00004756) | National Center for Research Resources (NCRR) | 1994-12-01 |
| Phase II/III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Mild to Moderate Systemic Lupus Erythematosus (NCT00004795) | National Center for Research Resources (NCRR) | 1994-08-01 |
| Study of Systemic Lupus Erythematosus (NCT00001372) | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 1994-02-10 |
| Epidemiologic Study of Reproductive Outcome in Women With Systemic Lupus Erythematosus (NCT00004663) | National Center for Research Resources (NCRR) | 1994-02-01 |
| Study of the Predictors of the Course and Early Outcome of Patients With Systemic Lupus Erythematosus: Nature Versus Nurture (NCT00006134) | National Center for Research Resources (NCRR) | 1993-09-01 |
| Ultraviolet Light Therapy for Systemic Lupus Erythematosus (NCT00004375) | National Center for Research Resources (NCRR) | 1991-09-01 |
| Drug Therapy in Lupus Nephropathy (NCT00001212) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1986-11-01 |
| Anifrolumab Early Access Program (NCT04750057) | AstraZeneca | |
| Compassionate Use for Subcutaneous (SC) Belimumab (NCT03125486) | GlaxoSmithKline | |